Treatment of meningeal breast cancer xenografts in the rat using an anti-P185/HER2 antibody

Clinical Cancer Research

Volumn 7, Issue 7, 2001, Pages 2050-2056

  Bergman, Ira ^a,b   Griffin, Judith A ^a   Barmada, Mamdouha A ^b   Slamon, Dennis J ^c  

^a Departments of Pediatrics   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIODY 4D5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; BREAST CANCER; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; LEPTOMENINX; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; BREAST NEOPLASMS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENTRICULAR; MENINGEAL NEOPLASMS; NEOPLASM TRANSPLANTATION; RATS; RATS, NUDE; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034777842     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Epidemiology
2. Carcinomatous meningitis secondary to breast cancer: Predictors of response to combined modality therapy
3. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients
4. Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant
5. Treatment for meningeal carcinomatosis in breast cancer
6. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment
7. Leptomeningeal metastases-treatment results in 98 consecutive patients
8. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-P185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
9. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who had HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
10. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
11. First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer: A preliminary report
12. p185neu expression in human lung adenocarcinomas predicts shortened survival
13. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
14. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: Correlation with overall survival
15. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast
16. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
17. Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase
18. Stability of HER-2/neu expression over time and at multiple metastatic sites
19. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth
20. p185HER2 signal transduction in breast cancer cells
21. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody
22. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
23. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to Her-2 receptor and DNA-reactive drugs
24. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
25. Radiolabeled antibody targeting of the HER-2/neu oncoprotein
26. Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration
27. Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meingeal neoplastic xenografts in nude rats
28. A rat model of leptomeningeal human neoplastic xenografts
29. Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8
30. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
31. Humanization of an anti-p185HER2 antibody for human cancer therapy
32. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu
33. Radioiodinated antibody targeting of the HER2/neu oncoprotein
34. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells
35. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-HER2 monoclonal antibodies
36. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
37. TGFα and the blood-brain barrier: Accumulation in cerebral vasculature
38. Estrogen -dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
39. Her-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
40. Ommaya reservoirs in 387 cancer patients: A 15-year experience
41. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloro-platinum against human breast and ovarian tumor cell lines
42. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair
43. Cerebrospinal fluid-platinum kinetics of cisplatin in man
44. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues
45. Requirement for neuregulin receptor erbB2 in neural and cardiac development
46. Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors